Bimolecular DNA vaccine of virus antigen-immune coactivator

A coactivator and DNA vaccine technology, applied in the field of biomedicine, can solve the problems of low immune response of specific antigens and failure to present them

Pending Publication Date: 2020-08-28
SICHUAN CHENGYU BIOLOGICAL PROD INC
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hybrid DNA vaccines are not effective at presenting both signals collectively to immu...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bimolecular DNA vaccine of virus antigen-immune coactivator
  • Bimolecular DNA vaccine of virus antigen-immune coactivator
  • Bimolecular DNA vaccine of virus antigen-immune coactivator

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0029] The embodiments of the present application will be described in detail below in conjunction with the accompanying drawings.

[0030] In order to make the purpose, technical solutions and advantages of the present application clearer, the present application will be described in further detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described here are only used to explain the present application, and are not intended to limit the present application.

[0031] The expression sites and functions of the human immune active factors in this application are as shown in the patent CN2019111493147, and will not be listed in detail in this application.

[0032] Such as figure 1 As shown, the present application discloses a bimolecular DNA vaccine of a viral antigen-immune coactivator, comprising an expression vector and a viral antigen molecule gene fragment and a human immune activity factor gene...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a bimolecular DNA vaccine of a virus antigen-immune coactivator, and relates to the technical field of biological medicines. An expression vector is a DNA plasmid; a virus antigen is any virus immunogenicity (antigen) molecule; and an immunocompetence factor is a T cell co-activation factor. According to the vaccine disclosed by the invention, an exogenous gene segment forexpressing a T cell co-activation factor and a virus gene segment of a virus antigen molecule are jointly constructed in the DNA plasmid and are simultaneously expressed in the same cell, and the double-molecule activates systematic immune response of T cells on virus. The bimolecular DNA vaccine is also a novel vaccine technology platform, and is suitable for developing preventive vaccines for various infectious diseases. Aiming at global COVID-19 prevalence, the bimolecular DNA vaccine of the new coronavirus S antigen fragment-immune co-activation factor can be constructed through the technical platform, and achieves immunoprophylaxis and control.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a bimolecular DNA vaccine of a viral antigen-immunity coactivator for preventing infectious diseases. Background technique [0002] The prevention and control of the new crown pneumonia epidemic is very important. In order to avoid the spread and spread of the epidemic, it is imminent to find a fast and effective vaccine to help us quickly form herd immunity, prevent the spread of the virus and prevent its large-scale spread. [0003] However, in the traditional vaccine development, the process of obtaining attenuated strains through a large number of passages and screening and identification is long. In addition, another bottleneck is the lack of animal models available in the development of COVID-19 vaccines, which makes it more difficult to pass passage and identify whether the selected attenuated vaccine strain is effective. At the same time, the development and screenin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/12A61K39/215A61K39/39A61K48/00A61P31/14A61P11/00
CPCA61K39/12A61K39/39A61K48/005A61K48/0025A61P31/14A61P11/00A61K2039/53A61K2039/55522C12N2770/20034A61K2300/00
Inventor 余力曾蓁曾莲张媚
Owner SICHUAN CHENGYU BIOLOGICAL PROD INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap